Chapter 3 Market and Technology Background
- Monoclonal Antibodies
- History of Monoclonal Antibodies
- Advantages and Disadvantages of Monoclonal Antibodies
- Monoclonal Antibodies in Oncology
- Types of Monoclonal Antibodies
Chapter 4 Market Dynamics
- Market Drivers
- Increasing Incidence of Cancer
- New Product Launches
- Rising Healthcare Expenditures and Government Funding
- Licensing and Collaboration Agreements
- Market Barriers
- Price Controls
- Regulatory Approval Pressures
- Entry of Biosimilars
- Opportunities
- Impact of Covid-19
Chapter 5 Market Breakdown by Type
- Types of Monoclonal Antibodies for Oncology
- Market Overview
- Market Revenue
- Global Market for Monoclonal Antibodies in Oncology by Type
- Humanized Monoclonal Antibodies
- Human Monoclonal Antibodies
- Chimeric Monoclonal Antibodies
Chapter 6 Market Breakdown by Application
- Overview
- Lung Cancer
- Market Size and Forecast
- Breast Cancer
- Market Size and Forecast
- Colorectal Cancer
- Market Size and Forecast
- Blood Cancer
- Market Size and Forecast
- Other Cancers
- Market Size and Forecast
Chapter 7 Market Breakdown by Region
- Introduction
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Rest of the World
- Market Size and Forecast
Chapter 8 Regulatory Aspects
- New Approvals of Monoclonal Antibodies for Oncology
- Recalls, Withdrawals, and Safety Alerts
Chapter 9 Patent Review/ New Developments
- New Developments
- Phase I Clinical Trials
- Phase Ii Clinical Trials
- Phase Iii Clinical Trials
Chapter 10 Competitive Landscape
- Mergers, Acquisitions, and Collaborations
- Company Market Shares
Chapter 11 Company Profiles
- Amgen Inc.
- Astrazeneca Pharmaceuticals
- Bristol-Myers Squibb
- Eli Lilly
- F. Hoffmann-La Roche AG
- GlaxoSmithKline
- Gilead Sciences Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Kgaa
- Pfizer Inc.
- Sanofi S.A.
- Seagen
List of Tables
Summary Table A: Global Market for Monoclonal Antibodies in Oncology, Through 2027
Summary Table B: Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2027
Table 1: Evolution of Monoclonal Antibodies
Table 2: Advantages and Disadvantages of Monoclonal Antibodies
Table 3: Monoclonal Antibodies Approved for Oncology
Table 4: Murine Monoclonal Antibodies
Table 5: Chimeric Monoclonal Antibodies
Table 6: Humanized Monoclonal Antibodies
Table 7: Human Monoclonal Antibodies
Table 8: Total Number of New Cases and Deaths Due to Various Cancers Globally, 2020
Table 9: Funding, by Research Areas, 2020
Table 10: Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2027
Table 11: Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 12: Global Market for Human Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 13: Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 14: Global Market for Monoclonal Antibodies in Oncology, by Application, Through 2027
Table 15: Global Market Market for Monoclonal Antibodies for Lung Cancer, by Region, Through 2027
Table 16: Global Market Market for Monoclonal Antibodies for Breast Cancer, by Region, Through 2027
Table 17: Global Market Market for Monoclonal Antibodies for Colorectal Cancer, by Region, Through 2027
Table 18: Global Market Market for Monoclonal Antibodies for Blood Cancer, by Region, Through 2027
Table 19: Numbers for All Cancers (Except Non-Melanoma Skin Cancer), 2020
Table 20: Global Market for Monoclonal Antibodies for Other Types of Blood Cancer, by Region, Through 2027
Table 21: Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 22: North American Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 23: Cancer Incidence and Mortality, Age Standardized Rate, per 100,000, by Cancer Type, EU Countries, 2020
Table 24: European Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 25: Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 26: Newly Approved Monoclonal Antibodies for Oncology, 2019-April 2022
Table 27: Recalls, Withdrawals, and Safety Alerts, 2019-April 2022
Table 28: Monoclonal Antibodies for Oncology in Phase I Clinical Trials
Table 29: Monoclonal Antibodies for Oncology in Phase II Clinical Trials
Table 30: Monoclonal Antibodies for Oncology in Phase III Clinical Trials
Table 31: M&A: Pharmaceutical Companies
Table 32: Sales of Blockbuster Monoclonal Antibodies for Oncology, 2021
Table 33: Amgen: Financial Performance, 2019-2021
Table 34: AstraZeneca: Financial Performance, 2019-2021
Table 35: AstraZeneca: Business Segment
Table 36: Bristol-Myers Squibb: Financial Performance, 2019-2021
Table 37: Eli Lilly: Business Segments
Table 38: Eli Lilly: Financial Performance, 2019-2021
Table 39: F. Hoffmann-La Roche: Business Segments
Table 40: F. Hoffmann-La Roche: Financial Performance, 2019-2021
Table 41: Johnson & Johnson: Business Segments
Table 42: Johnson & Johnson: Financial Performance, 2019-2021
Table 43: Merck & Co. Inc.: Business Segment
Table 44: Merck & Co. Inc.: Financial Performance, 2019-2021
Table 45: Pfizer: Business Segment
Table 46: Pfizer: Financial Performance, 2019-2021
Table 47: Sanofi: Business Segments
List of Figures
Summary Figure A: Global Market for Monoclonal Antibodies in Oncology, 2020-2027
Summary Figure B: Global Market for Monoclonal Antibodies in Oncology, by Type, 2020-2027
Figure 1: Approved Antibody Therapeutics in the U.S. and EU, 2010-2021
Figure 2: Global Estimated New Cancer Cases, by Region, 2020 vs. 2040
Figure 3: Global Market for Monoclonal Antibodies in Oncology, by Type, 2020-2027
Figure 4: Global Market Shares of Monoclonal Antibodies in Oncology, by Type, 2021
Figure 5: Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 6: Global Market for Human Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 7: Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 8: Global Market for Monoclonal Antibodies in Oncology, by Application, 2020-2027
Figure 9: Global Market Shares of Monoclonal Antibodies in Oncology, by Application, 2021
Figure 10: Global Market for Monoclonal Antibodies for Lung Cancer, by Region, 2020-2027
Figure 11: Global Market for Monoclonal Antibodies for Breast Cancer, by Region, 2020-2027
Figure 12: Global Market for Monoclonal Antibodies for Colorectal Cancer, by Region, 2020-2027
Figure 13: Global Market for Monoclonal Antibodies for Blood Cancer, by Region, 2020-2027
Figure 14: Global Market for Monoclonal Antibodies for Other Types of Blood Cancer, by Region, 2020-2027
Figure 15: Global Market for Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 16: Global Market Shares of Monoclonal Antibodies in Oncology, by Region, 2021
Figure 17: North American Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027
Figure 18: U.S. Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 19: Canadian Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 20: European Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027
Figure 21: German Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 22: U.K. Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 23: French Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 24: Italian Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 25: Spanish Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 26: Rest of European Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 27: Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027
Figure 28: Chinese Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 29: Indian Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 30: Japanese Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 31: Rest of Asia-Pacific Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 32: Rest of the World Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 33: Global Manufacturer/Supplier Market Shares of Monoclonal Antibodies in Oncology, 2021
Figure 34: Amgen: Annual Revenue, 2019-2021
Figure 35: Amgen: Total Sales Share, by Product, 2021
Figure 36: Amgen: Total Revenue Share, by Region, 2021
Figure 37: AstraZeneca: Annual Revenue, 2019-2021
Figure 38: AstraZeneca: Total Sales Share, by Segment, 2021
Figure 39: AstraZeneca: Total Revenue Share, by Region, 2021
Figure 40: Bristol-Myers Squibb: Annual Revenue, 2019-2021
Figure 41: Bristol Myers Squibb: Total Sales Share, by Product, 2021
Figure 42: Bristol-Myers Squibb: Total Revenue Share, by Region, 2021
Figure 43: Eli Lilly: Annual Revenue, 2019-2021
Figure 44: Eli Lilly: Total Sales Share, by Product Segment, 2021
Figure 45: Eli Lilly: Total Revenue Share, by Region, 2021
Figure 46: F. Hoffmann-La Roche: Annual Revenue, 2019-2021
Figure 47: F. Hoffmann-La Roche: Total Sales Share, by Pharmaceutical Segment, 2021
Figure 48: F. Hoffmann-La Roche: Total Revenue Share, by Region, 2021
Figure 49: Johnson & Johnson: Annual Revenue, 2019-2021
Figure 50: Johnson & Johnson: Total Sales Share, by Business Segment, 2021
Figure 51: Johnson & Johnson: Total Revenue Share, by Region, 2021
Figure 52: Merck & Co. Inc.: Annual Revenue, 2019-2021
Figure 53: Merck & Co. Inc.: Revenue Share, by Business Segment, 2021
Figure 54: Merck & Co. Inc.: Revenue Share, by Region, 2021
Figure 55: Pfizer: Annual Revenue, 2019-2021
Figure 56: Pfizer: Net Sales Share, by Business Segment, 2021
Figure 57: Pfizer: Net Sales Share, by Region, 2021
